Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) saw a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 8,700,000 shares, a drop of 15.7% from the June 30th total of 10,320,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is currently 6.8 days.
Wall Street Analyst Weigh In
Separately, StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.
Read Our Latest Analysis on Aurinia Pharmaceuticals
Institutional Trading of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Down 0.4 %
Aurinia Pharmaceuticals stock traded down $0.02 during trading hours on Tuesday, hitting $5.66. 814,658 shares of the stock traded hands, compared to its average volume of 1,763,006. The firm’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $5.80. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The company has a market cap of $809.49 million, a PE ratio of -13.19 and a beta of 1.44. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $12.38.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.14. The business had revenue of $50.30 million for the quarter, compared to analysts’ expectations of $46.30 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. On average, research analysts forecast that Aurinia Pharmaceuticals will post 0.15 EPS for the current year.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Insider Buying Explained: What Investors Need to Know
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- What is a SEC Filing?
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.